首页> 外文OA文献 >Cellular induction of chronic allotype suppression of IgG2a in Ighb/b homozygous mice and its abrogation by in vivo treatment with anti-CD8 monoclonal antibody
【2h】

Cellular induction of chronic allotype suppression of IgG2a in Ighb/b homozygous mice and its abrogation by in vivo treatment with anti-CD8 monoclonal antibody

机译:细胞抗Ighb / b纯合子小鼠IgG2a慢性同种异型抑制的细胞诱导及其体内抗CD8单克隆抗体的治疗作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report here the successful induction of allotype suppression in homozygous Ighb/b mice (CB20 or C57BL/6) by neonatal injection of T splenocytes from Igha congenic sensitized mice (BALB/c or BC8, respectively). The sensitization of the T cell donors was achieved by two intravenous injections of B splenocytes from Ighb congenic mice. Treated homozygous Ighb/b mice developed, as of 16-24 wk of age, a chronic suppression of Igh-1b expression (IgG2a of Ighb haplotype). The other productions tested (IgM, IgD, and IgA) of Ighb haplotype were unaffected. In vivo treatment with cytotoxic anti-CD4 or anti-CD8 mAb of mice subjected to chronic Igh-1b suppression clearly showed that CD8+ lymphocytes (suppressor or cytotoxic cell) were essential for the maintenance of the suppression. The suppression was indeed abrogated after a 1-wk treatment with anti-CD8 mAb containing culture supernatant, whereas, the anti-CD4-treated mice continued to be subjected to suppression. This anti-CD8 in vivo treatment was shown to have no effect on thymus but to severely reduce the percentages of CD8+ cells in spleen and in peripheral blood without affecting the percentages of CD4+ cells, leading to a large and rapid Igh-1b expression (up to 0.5 mg per ml of serum, the day after the end of the treatment). This suppression abrogation, and thus the Igh-1b expression, was either transient or permanent. When it was transient, a second 1-wk treatment with anti-CD8 mAb containing culture supernatant induced once again a rapid and significant production of Igh-1b (up to 0.3 mg of Igh-1b per ml of serum).
机译:我们在这里报告通过新生注射来自Igha同基因致敏小鼠(分别为BALB / c或BC8)的T脾细胞,在纯合Ighb / b小鼠(CB20或C57BL / 6)中成功诱导了同种异型抑制。通过两次静脉注射来自Ighb同系小鼠的B脾细胞来实现T细胞供体的敏化。从16-24周龄开始,经过治疗的纯合Ighb / b小鼠发展为Igh-1b表达(Ighb单倍型IgG2a)的慢性抑制。测试的其他Ighb单倍型产品(IgM,IgD和IgA)不受影响。接受Igh-1b慢性抑制的小鼠体内用细胞毒性抗CD4或抗CD8 mAb进行的体内治疗清楚地表明,CD8 +淋巴细胞(抑制剂或细胞毒性细胞)对于维持抑制至关重要。在用含有抗CD8 mAb的培养上清液进行1 wk处理后,抑制作用的确消除了,而经抗CD4处理的小鼠继续受到抑制作用。已证明这种抗CD8的体内治疗对胸腺无影响,但会严重降低脾脏和外周血中CD8 +细胞的百分比,而不会影响CD4 +细胞的百分比,从而导致Igh-1b大量快速表达(向上在治疗结束后的第二天,每毫升血清0.5 mg。这种抑制废除,从而Igh-1b表达,是短暂的或永久的。当它是短暂的时,用含有培养上清液的抗CD8 mAb进行的第二次1周处理再次诱导了Igh-1b的快速大量生产(每毫升血清最多0.3 mg Igh-1b)。

著录项

  • 作者

  • 作者单位
  • 年度 1988
  • 总页数
  • 原文格式 PDF
  • 正文语种 {"code":"en","name":"English","id":9}
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号